MRK-409

MRK-409^[1]

Names
IUPAC name 7-Cyclobutyl-3-(2,6-difluorophenyl)-6-[(2-methyl-1,2,4-triazol-3-yl)methoxy]-[1,2,4]triazolo[4,3-b]pyridazine
Other names MK-0343 1,2,4-Triazolo(4,3-b)pyridazine, 7-cyclobutyl-3-(2,6-difluorophenyl)-6-((1-methyl-1H-1,2,4-triazol-5-yl)methoxy)-
Identifiers
CAS Number	233275-76-8
3D model ( JSmol )	Interactive image
ChEMBL	ChEMBL4303594
ChemSpider	11499267
DrugBank	DB13993
PubChem CID	22609888
UNII	9VSE02330I
InChI InChI=1S/C19H17F2N7O/c1-27-16(22-10-23-27)9-29-19-12(11-4-2-5-11)8-15-24-25-18(28(15)26-19)17-13(20)6-3-7-14(17)21/h3,6-8,10-11H,2,4-5,9H2,1H3 Key: GOIFCXRIFSYPFG-UHFFFAOYSA-N
SMILES CN1C(=NC=N1)COC2=NN3C(=NN=C3C4=C(C=CC=C4F)F)C=C2C5CCC5
Properties
Chemical formula	C19H17F2N7O
Molar mass	397.390 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

MRK-409, also known as MK-0343, is a GABA_A receptor partial agonist.^[2]

It was designed to be a non-sedative anxiolytic, however its development was halted because it produced sedation in humans.^[3]

Pharmacodynamics

Despite lacking the benzodiazepine chemical structure, MRK-409 acts on the benzodiazepine binding site, it is therefore a nonbenzodiazepine.

MRK-409 binds to the α1, α2, α3 and α5 subunits of the GABA_A receptor.^[4]

In rats, it produces minimal to no sedation, however it produces sedation in humans at doses above 1 mg.^[3][5]

References